4/9
09:00 am
spry
ARS Pharmaceuticals (SPRY) is now covered by Northland Securities. They set an "outperform" rating and a $25.00 price target on the stock.
Low
Report
ARS Pharmaceuticals (SPRY) is now covered by Northland Securities. They set an "outperform" rating and a $25.00 price target on the stock.
4/9
06:53 am
spry
ARS Pharmaceuticals initiated with an Outperform at Northland
Low
Report
ARS Pharmaceuticals initiated with an Outperform at Northland